Table 2

Crude incidence rates and adjusted HR for breast cancer risk among glargine users compared with NPH users, by ever use, duration of use, cumulative dose, and length of follow-up

UsersBreast cancersPY of follow-upCrude breast cancer incidence rate per 1,000 PY (95% CI)Unweighted HR (95% CI)Weighted HR (95% CI)
Ever use
 Glargine203,1594,170691,3426.03 (5.85–6.21)1.00 (0.93–1.08)0.97 (0.88–1.06)
 NPH47,388864143,6286.02 (5.61–6.42)RefRef
Duration of use (years)
 Glargine 0 to <3203,1593,675612,5566.00 (5.81–6.19)0.98 (0.91–1.06)0.96 (0.87–1.06)
 NPH 0 to <347,388793129,4646.13 (5.70–6.55)RefRef
 Glargine 3 to <537,14339261,5926.36 (5.73–6.99)1.33 (0.99–1.77)1.11 (0.76–1.62)
 NPH 3 to <55,6945210,7984.82 (3.51–6.12)RefRef
 Glargine ≥510,87510317,1945.99 (4.83–7.15)1.06 (0.65–1.74)0.68 (0.37–1.24)
 NPH ≥51,847193,3655.65 (3.11–8.18)RefRef
Cumulative dose (units)
 Glargine 0 to <20,000203,1592,835475,0805.97 (5.75–6.19)0.98 (0.89–1.07)0.96 (0.86–1.08)
 NPH 0 to <20,00047,38857493,9946.11 (5.61–6.61)RefRef
 Glargine 20,000 to <60,00079,4941,014169,8175.97 (5.60–6.34)1.06 (0.91–1.24)0.99 (0.81–1.22)
 NPH 20,000 to <60,00016,66319834,0295.82 (5.01–6.63)RefRef
 Glargine ≥60,00021,31832146,4466.91 (6.16–7.67)1.29 (1.02–1.63)1.14 (0.83–1.56)
 NPH ≥60,0005,9249215,6055.90 (4.69–7.10)RefRef
Length of follow-up (years)
 Glargine 0 to <3203,1592,780447,5396.21 (5.98–6.44)0.96 (0.88–1.05)0.95 (0.85–1.06)
 NPH 0 to <347,38860393,5196.45 (5.93–6.96)RefRef
 Glargine 3 to <598,328840143,5685.85 (5.46–6.25)1.08 (0.91–1.28)1.03 (0.83–1.28)
 NPH 3 to <519,15015428,3815.43 (4.57–6.28)RefRef
 Glargine ≥549,515550100,2355.49 (5.03–5.95)1.11 (0.90–1.37)0.97 (0.74–1.26)
 NPH ≥510,13610721,7284.92 (3.99–5.86)RefRef
  • Data are n unless otherwise indicated. Ref, reference.